StartsideCMPS • NASDAQ
add
Compass Pathways PLC
3,67 $
Etterbørs:(2,18 %)+0,080
3,75 $
Stengt: 3. mars, 16:04:27 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Forrige sluttkurs
3,93 $
Dagsintervall
3,66 $ - 4,10 $
Årsintervall
3,17 $ - 12,57 $
Markedsverdi
339,20 mill. USD
Gjennomsnittlig volum
1,18 mill.
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | des. 2024info | Endring år til år |
|---|---|---|
Omsetning | — | — |
Driftskostnader | 38,21 mill. | 9,02 % |
Nettoomsetning | −43,33 mill. | −33,20 % |
Netto resultatmargin | — | — |
Fortjeneste per aksje | −0,63 | −18,87 % |
EBITDA | −38,16 mill. | −9,06 % |
Faktisk avgiftssats | −2,42 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | des. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 165,08 mill. | −25,03 % |
Totale aktiva | 213,67 mill. | −22,58 % |
Totale passiva | 58,97 mill. | 17,37 % |
Total egenkapital | 154,70 mill. | — |
Utestående aksjer | 92,67 mill. | — |
P/B-forhold | 1,74 | — |
Avkastning på aktiva | −41,44 % | — |
Avkastning på kapital | −46,32 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | des. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | −43,33 mill. | −33,20 % |
Kontantstrøm fra drift | −41,76 mill. | −50,30 % |
Kontanter fra investering | — | — |
Kontanter fra finansiering | 155,00k | 278,05 % |
Netto kontantstrøm | −41,87 mill. | −50,99 % |
Fri kontantstrøm | −44,04 mill. | −133,07 % |
Om
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Grunnlagt
13. juni 2016
Nettsted
Ansatte
166
